UNSPSC 51113303: Uredepa

This classification denotes an ethylenimine compound with the molecular formula C7H14N3O3P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9V30JZ75AB, chemically known as carbamic acid, (bis(1-aziridinyl)phosphinyl)-, ethyl ester but more generally known as uredepa, which bears US NIH Compound Identifier 9332. European Medicines Agency schedules Uredepa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11385MIG.

UNSPSC 51113303 Uredepa is a Commodity code tracking state and local procurement of pharmaceutical products and related services, specifically direct-to-manufacturer prescription fulfillment and pharmacy benefit management arrangements. State and local governments buy under this code when they seek to establish or modify pharmacy benefit programs, negotiate direct manufacturer contracts to bypass traditional pharmacy benefit managers and group purchasing organizations, and implement value-based or outcomes-based pharmaceutical pricing agreements. Issuing bodies include state health and human services departments and health plan administrators managing prescription benefits for employee and retiree populations. The Texas Health and Human Services Commission is a significant recent buyer in this space, signaling that state health agencies are actively exploring alternative pharmacy distribution and pricing models to reduce costs and improve fulfillment efficiency.

Texas represents the geographic focus of recent activity under this code. The Texas Health and Human Services Commission posted a Request for Information (RFI HHS0017013) on March 27, 2026, with a response deadline of April 3, 2026, seeking vendor capabilities regarding direct-to-manufacturer prescription programs designed to serve self-insured employee group health plans and state agencies outside traditional PBM and group purchasing organization channels. The RFI solicits information about vendors' experience with direct contracting, flexibility to negotiate net-pricing models without rebates, and capacity to support value-based pharmaceutical agreements. This exploratory phase precedes formal procurement, indicating the state intends to use vendor responses to develop detailed specifications and implementation timelines for subsequent RFPs. No award values, budget ranges, or set-asides are specified in the current RFI materials.